title: Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
abstract: OBJECTIVE
  Examine the incidence of clinical events after utilization of the TAXUS(®) Express(®) paclitaxel-eluting stent (PES) in multivessel and bifurcation coronary stenting in an unselected patient population.
  
  
  RESULTS
  The ARRIVE Program compiled data on 7,492 patients receiving ≥1 TAXUS Express PES, including patients with multivessel stenting (MVS; n = 1,208) and bifurcation stenting (n = 575). Patients were enrolled at procedure start with no mandated inclusion/exclusion criteria; all cardiac events were monitored with independent adjudication of end-points. Compared to simple use (single vessel/single stent) patients undergoing native intervention (N = 2,698), MVS patients had significantly more baseline comorbidities. Both groups had higher 2-year rates of mortality (7.3%[MVS] and 7.5%[bifurcation] vs. 4.2%[simple-use], P < 0.001), myocardial infarction (5.5% and 4.6% vs. 2.2%, P < 0.001 and P = 0.002), target vessel revascularization (15.5% and 14.8% vs. 7.7%, P < 0.001), and Academic Research Consortium definite/probable stent thrombosis (4.3% and 4.4% vs. 1.4%, P < 0.001) than the simple-use group.
  
  
  CONCLUSIONS
  ARRIVE multivessel and bifurcation stenting patients have significantly higher clinical risk through 2 years compared to simple-use patients. In the absence of large randomized controlled trials in these populations, ARRIVE provides important insight into clinical outcomes over an extended period of time. (J Interven Cardiol 2011;24:342-350).
authors.affiliation: VA North Texas Healthcare System and University of Texas, Southwestern Medical Center at Dallas, USA. esbrilakis@yahoo.com
authors.forename: Emmanouil S
authors.initials: ES
authors.lastname: Brilakis
authors.forename: John M
authors.initials: JM
authors.lastname: Lasala
authors.forename: David A
authors.initials: DA
authors.lastname: Cox
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Bowman
authors.forename: Ruth M
authors.initials: RM
authors.lastname: Starzyk
authors.forename: Keith D
authors.initials: KD
authors.lastname: Dawkins
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D009204:Myocardial Revascularization; D017239:Paclitaxel; D011446:Prospective Studies; D012042:Registries; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel